These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38390615)

  • 1. Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice.
    El Jordi O; Fischer KD; Meyer TB; Atwood BK; Oblak AL; Pan RW; McKinzie DL
    Adv Drug Alcohol Res; 2022; 2():10848. PubMed ID: 38390615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sexually dimorphic neuroimmune response to chronic opioid treatment and withdrawal.
    Kumar M; Rainville JR; Williams K; Lile JA; Hodes GE; Vassoler FM; Turner JR
    Neuropharmacology; 2021 Mar; 186():108469. PubMed ID: 33485944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and validation of a spontaneous acute and protracted oxycodone withdrawal model in male and female mice.
    Contreras KM; Buzzi B; Vaughn J; Caillaud M; Altarifi AA; Olszewski E; Walentiny DM; Beardsley PM; Damaj MI
    Pharmacol Biochem Behav; 2024 Sep; 242():173795. PubMed ID: 38834159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurophysiological response properties of medullary pain-control neurons following chronic treatment with morphine or oxycodone: modulation by acute ketamine.
    Viisanen H; Lilius TO; Sagalajev B; Rauhala P; Kalso E; Pertovaara A
    J Neurophysiol; 2020 Sep; 124(3):790-801. PubMed ID: 32755331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglial depletion alters the brain neuroimmune response to acute binge ethanol withdrawal.
    Walter TJ; Crews FT
    J Neuroinflammation; 2017 Apr; 14(1):86. PubMed ID: 28427424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.
    Bhalla S; Pais G; Tapia M; Gulati A
    Can J Physiol Pharmacol; 2015 Nov; 93(11):935-44. PubMed ID: 26440527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic changes in microglia in the mouse hippocampus during administration and withdrawal of the CSF1R inhibitor PLX3397.
    Wang Q; Wang YY; Pu WJ; Ma X; Ni RJ
    J Anat; 2023 Sep; 243(3):394-403. PubMed ID: 37038887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mu opioid receptor in microglia contributes to morphine analgesic tolerance, hyperalgesia, and withdrawal in mice.
    Reiss D; Maduna T; Maurin H; Audouard E; Gaveriaux-Ruff C
    J Neurosci Res; 2022 Jan; 100(1):203-219. PubMed ID: 32253777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD006332. PubMed ID: 36106667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Ultramicronized
    Micheli L; Lucarini E; Toti A; Ferrara V; Ciampi C; Parisio C; Bartolucci G; Di Cesare Mannelli L; Ghelardini C
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
    Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
    Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement.
    Drinkuth CR; Lehane MJ; Sartor GC
    Drug Alcohol Depend; 2023 Dec; 253():110987. PubMed ID: 37864957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-specific role for serotonin 5-HT
    Sierra S; Muchhala KH; Jessup DK; Contreras KM; Shah UH; Stevens DL; Jimenez J; Cuno Lavilla XK; de la Fuente Revenga M; Lippold KM; Shen S; Poklis JL; Qiao LY; Dewey WL; Akbarali HI; Damaj MI; González-Maeso J
    Neuropharmacology; 2022 May; 209():108988. PubMed ID: 35183539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells.
    Okojie AK; Uweru JO; Coburn MA; Li S; Cao-Dao VD; Eyo UB
    J Neuroinflammation; 2023 Oct; 20(1):242. PubMed ID: 37865779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast).
    Hutchinson MR; Lewis SS; Coats BD; Skyba DA; Crysdale NY; Berkelhammer DL; Brzeski A; Northcutt A; Vietz CM; Judd CM; Maier SF; Watkins LR; Johnson KW
    Brain Behav Immun; 2009 Feb; 23(2):240-50. PubMed ID: 18938237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endomorphin analog ZH853 shows low reward, tolerance, and affective-motivational signs of withdrawal, while inhibiting opioid withdrawal and seeking.
    Amgott-Kwan AT; Zadina JE
    Neuropharmacology; 2023 Apr; 227():109439. PubMed ID: 36709036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits.
    Henry RJ; Ritzel RM; Barrett JP; Doran SJ; Jiao Y; Leach JB; Szeto GL; Wu J; Stoica BA; Faden AI; Loane DJ
    J Neurosci; 2020 Apr; 40(14):2960-2974. PubMed ID: 32094203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference.
    Iyer V; Woodward TJ; Pacheco R; Hohmann AG
    Neuropharmacology; 2022 Mar; 205():108925. PubMed ID: 34921830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.